Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(18):1526-1527; doi:10.1093/jnci/91.18.1526
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tochner, Z. A.
Right arrow Articles by Glatstein, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tochner, Z. A.
Right arrow Articles by Glatstein, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 18, 1526-1527, September 15, 1999
© 1999 Oxford University Press

EDITORIALS

Photoimmunotherapy and Ovarian Cancer: an Improbable Fiction or a Palpable Hit?

 "If this were played upon a stage now

 I could condemn it as an improbable fiction."

  —William Shakespeare, Twelfth Night, Act 3, Scene 4

Zelig A. Tochner, Stephen Hahn, Eli Glatstein

Affiliation of authors: Radiation Oncology Department, The Hospital of the University of Pennsylvania School of Medicine, Philadelphia.

Correspondence to: Zelig A. Tochner, M.D., Radiation Oncology Department, The Hospital of the University of Pennsylvania School of Medicine, 3400 Spruce St., 2 Donner, Philadelphia, PA 19104.

For more than two decades, epithelial carcinoma of the ovary has been the number 1 killer of U.S. women with cancers of the female genital tract (1). Despite impressive response rates to combination chemotherapy, the large majority of tumors recur, and fewer than 20% of women who present with advanced disease will survive 10 years (2). Long-term survival figures with modern combinations of paclitaxel and platinum-based drugs are only slightly better than the survival figures with platinum-based combination chemotherapy studies of the late 1970s (2-4).

Ongoing clinical research has focused primarily on the role of surgery and the development of new chemotherapy agents. The . . . [Full Text of this Article]

REFERENCES


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?